64Cu-DOTA-AE105

N/A

Report date: 2025/11/19 17:58:24

NME

Base Information

Drug Name64Cu-DOTA-AE105

Drug Alias NameCopper-64 DOTA AE10564Cu-DOTA-AE105

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersUrokinase plasminogen activator surface receptor inhibitors

TargetsUrokinase plasminogen activator surface receptor

Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwedenDenmark

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRigshospitalet

China Registration ClassN/A

Develop Information

Active CompaniesCurasight Aps

Inactive CompaniesRigshospitalet

Active IndicationsProstatic Neoplasms

Inactive IndicationsUrinary Bladder NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A